Analysis of Over 10,000 Cases Finds No Association between Previously Reported Candidate Polymorphisms and Ovarian Cancer Outcome

 
Thumbnail
View/Open
Author
White, K. L.
Vierkant, R. A.
Fogarty, Z. C.
Charbonneau, B.
Block, M. S.
Pharoah, P. D. P.
Chenevix-Trench, G.
Rossing, M. A.
Pearce, C. L.
Schildkraut, J. M.
Menon, U.
Kjaer, S. K.
Levine, D. A.
Gronwald, J.
Culver, H. A.
Whittemore, A. S.
Karlan, B. Y.
Lambrechts, D.
Wentzensen, N.
Kupryjanczyk, J.
Chang-Claude, J.
Bandera, E. V.
Hogdall, E.
Heitz, F.
Kaye, S. B.
Fasching, P. A.
Campbell, I.
Goodman, M. T.
Pejovic, T.
Bean, Y.
Lurie, G.
Eccles, D.
Hein, A.
Beckmann, M. W.
Ekici, A. B.
Paul, J.
Brown, R.
Flanagan, J. M.
Harter, P.
du Bois, A.
Schwaab, I.
Hogdall, C. K.
Lundvall, L.
Olson, S. H.
Orlow, I.
Paddock, L. E.
Rudolph, A.
Eilber, U.
Dansonka-Mieszkowska, A.
Rzepecka, I. K.
Ziolkowska-Seta, I.
Brinton, L.
Yang, H.
Garcia-Closas, M.
Despierre, E.
Lambrechts, S.
Vergote, I.
Walsh, C.
Lester, J.
Sieh, W.
McGuire, V.
Rothstein, J. H.
Ziogas, A.
Lubinski, J.
Cybulski, C.
Menkiszak, J.
Jensen, A.
Gayther, S. A.
Ramus, S. J.
Gentry-Maharaj, A.
Berchuck, A.
Wu, A. H.
Pike, M. C.
Van DenBerg, D.
Vitonis, A. F.
Doherty, J. A.
Johnatty, S. E.
deFazio, A.
Song, H.
Tyrer, J.
Sellers, T. A.
Phelan, C. M.
Kalli, K. R.
Cunningham, J. M.
Fridley, B. L.
Goode, E. L.
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.1158/1055-9965.EPI-13-0028
Metadata
Show full item record
Citation
White, K. L., R. A. Vierkant, Z. C. Fogarty, B. Charbonneau, M. S. Block, P. D. P. Pharoah, G. Chenevix-Trench, et al. 2013. “Analysis of Over 10,000 Cases Finds No Association Between Previously Reported Candidate Polymorphisms and Ovarian Cancer Outcome.” Cancer Epidemiology Biomarkers & Prevention 22 (5) (March 19): 987–992. doi:10.1158/1055-9965.epi-13-0028.
Abstract
Background

Ovarian cancer is a leading cause of cancer-related death among women. In an effort to understand contributors to disease outcome, we evaluated single-nucleotide polymorphisms (SNPs) previously associated with ovarian cancer recurrence or survival, specifically in angiogenesis, inflammation, mitosis, and drug disposition genes.

Methods

Twenty-seven SNPs in VHL, HGF, IL18, PRKACB, ABCB1, CYP2C8, ERCC2, and ERCC1 previously associated with ovarian cancer outcome were genotyped in 10,084 invasive cases from 28 studies from the Ovarian Cancer Association Consortium with over 37,000 observed person-years and 4,478 deaths. Cox proportional hazards models were used to examine the association between candidate SNPs and ovarian cancer recurrence or survival with and without adjustment for key covariates.

Results

We observed no association between genotype and ovarian cancer recurrence or survival for any of the SNPs examined.

Conclusions

These results refute prior associations between these SNPs and ovarian cancer outcome and underscore the importance of maximally powered genetic association studies.

Impact

These variants should not be used in prognostic models. Alternate approaches to uncovering inherited prognostic factors, if they exist, are needed.
Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3650102/
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:27336539

Collections